Semaglutide for managing overweight and obesity : NICE guidance summary

The following table provides a comprehensive overview of the criteria and recommendations associated with the use of semaglutide for weight management as suggested by NICE. Semaglutide is a medication considered for weight loss and maintenance, in conjunction with a reduced-calorie diet and heightened physical activity.

Criteria/Recommendation	Details/Conditions
Duration of Semaglutide Use	To be used for a maximum duration of 2 years.
Setting for Treatment	Treatment should be administered within a specialist weight management service that offers multidisciplinary management of overweight or obesity. This can include tier 3 and 4 services.
Comorbidity Requirement	Patients should have at least one weight-related comorbidity AND
Body Mass Index (BMI) Criteria	Two scenarios qualify: • A BMI of at least 35.0 kg/m^2 OR • A BMI between 30.0 kg/m^2 and 34.9 kg/m^2, but the patient should meet the criteria for referral to specialist weight management services as per NICE's guidelines.
Provision Terms	The drug company must provide semaglutide according to the pre-agreed commercial arrangement.
BMI Adjustments for Specific Ethnic Groups	People from backgrounds like South Asian, Chinese, other Asian, Middle Eastern, Black African, or African Caribbean usually have their BMI thresholds lowered by 2.5 kg/m^2.
Criteria to Consider Stopping Treatment	Treatment may be halted if...

Try our Free Plan to get the full article.